134 related articles for article (PubMed ID: 28415748)
1. The Spi1/PU.1 transcription factor accelerates replication fork progression by increasing PP1 phosphatase in leukemia.
Rimmelé P; Esposito M; Delestré L; Guervilly JH; Ridinger-Saison M; Despras E; Moreau-Gachelin F; Rosselli F; Guillouf C
Oncotarget; 2017 Jun; 8(23):37104-37114. PubMed ID: 28415748
[TBL] [Abstract][Full Text] [Related]
2. Spi-1/PU.1 oncogene accelerates DNA replication fork elongation and promotes genetic instability in the absence of DNA breakage.
Rimmelé P; Komatsu J; Hupé P; Roulin C; Barillot E; Dutreix M; Conseiller E; Bensimon A; Moreau-Gachelin F; Guillouf C
Cancer Res; 2010 Sep; 70(17):6757-66. PubMed ID: 20660370
[TBL] [Abstract][Full Text] [Related]
3. Senescence is a Spi1-induced anti-proliferative mechanism in primary hematopoietic cells.
Delestré L; Cui H; Esposito M; Quiveron C; Mylonas E; Penard-Lacronique V; Bischof O; Guillouf C
Haematologica; 2017 Nov; 102(11):1850-1860. PubMed ID: 28912174
[TBL] [Abstract][Full Text] [Related]
4. CHK1 and replicative stress in T-cell leukemia: Can an irreverent tumor suppressor end up playing the oncogene?
Sarmento LM; Barata JT
Adv Biol Regul; 2016 Jan; 60():115-121. PubMed ID: 26527132
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation of the proto-oncogene Zfp521 by SPI1 (PU.1) and HOXC13.
Yu M; Al-Dallal S; Al-Haj L; Panjwani S; McCartney AS; Edwards SM; Manjunath P; Walker C; Awgulewitsch A; Hentges KE
Genesis; 2016 Oct; 54(10):519-533. PubMed ID: 27506447
[TBL] [Abstract][Full Text] [Related]
6. A somatic mutation of GFI1B identified in leukemia alters cell fate via a SPI1 (PU.1) centered genetic regulatory network.
Anguita E; Gupta R; Olariu V; Valk PJ; Peterson C; Delwel R; Enver T
Dev Biol; 2016 Mar; 411(2):277-286. PubMed ID: 26851695
[TBL] [Abstract][Full Text] [Related]
7. The actin-binding protein CORO1A is a novel PU.1 (SPI1)- and CEBPA-regulated gene with significantly lower expression in APL and CEBPA-mutated AML patients.
Federzoni EA; Humbert M; Valk PJ; Behre G; Leibundgut EO; Torbett BE; Fey MF; Tschan MP
Br J Haematol; 2013 Mar; 160(6):855-9. PubMed ID: 23252456
[No Abstract] [Full Text] [Related]
8. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
[TBL] [Abstract][Full Text] [Related]
9. Metallothionein-1 isoforms and vimentin are direct PU.1 downstream target genes in leukemia cells.
Imoto A; Okada M; Okazaki T; Kitasato H; Harigae H; Takahashi S
J Biol Chem; 2010 Apr; 285(14):10300-9. PubMed ID: 20139074
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of protein phosphatase-1 and -2A decreases the chemosensitivity of leukemic cells to chemotherapeutic drugs.
Dedinszki D; Kiss A; Márkász L; Márton A; Tóth E; Székely L; Erdődi F
Cell Signal; 2015 Feb; 27(2):363-72. PubMed ID: 25435424
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia.
Van Thillo Q; De Bie J; Seneviratne JA; Demeyer S; Omari S; Balachandran A; Zhai V; Tam WL; Sweron B; Geerdens E; Gielen O; Provost S; Segers H; Boeckx N; Marshall GM; Cheung BB; Isobe K; Kato I; Takita J; Amos TG; Deveson IW; McCalmont H; Lock RB; Oxley EP; Garwood MM; Dickins RA; Uyttebroeck A; Carter DR; Cools J; de Bock CE
Nat Commun; 2021 Jul; 12(1):4164. PubMed ID: 34230493
[TBL] [Abstract][Full Text] [Related]
12. CircSPI1 acts as an oncogene in acute myeloid leukemia through antagonizing SPI1 and interacting with microRNAs.
Wang X; Jin P; Zhang Y; Wang K
Cell Death Dis; 2021 Mar; 12(4):297. PubMed ID: 33741901
[TBL] [Abstract][Full Text] [Related]
13. Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding.
Seshire A; Rößiger T; Frech M; Beez S; Hagemeyer H; Puccetti E
Leukemia; 2012 Jun; 26(6):1338-47. PubMed ID: 22105598
[TBL] [Abstract][Full Text] [Related]
14. Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents.
Bašová P; Paszeková H; Minařík L; Dluhošová M; Burda P; Stopka T
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743167
[TBL] [Abstract][Full Text] [Related]
15. Forced FOG1 expression in erythroleukemia cells: Induction of erythroid genes and repression of myelo-lymphoid transcription factor PU.1.
Fujiwara T; Sasaki K; Saito K; Hatta S; Ichikawa S; Kobayashi M; Okitsu Y; Fukuhara N; Onishi Y; Harigae H
Biochem Biophys Res Commun; 2017 Apr; 485(2):380-387. PubMed ID: 28216155
[TBL] [Abstract][Full Text] [Related]
16. PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.
Albajar M; Gutierrez P; Richard C; Rosa-Garrido M; Gómez-Casares MT; Steegmann JL; León J; Delgado MD
Cancer Lett; 2008 Nov; 270(2):328-36. PubMed ID: 18635311
[TBL] [Abstract][Full Text] [Related]
17. The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis.
Burda P; Laslo P; Stopka T
Leukemia; 2010 Jul; 24(7):1249-57. PubMed ID: 20520638
[TBL] [Abstract][Full Text] [Related]
18. Correlation of PU.1 and signal regulatory protein α1 expression in PU.1 transgenic K562 cells.
Iseki Y; Nakahara M; Kubo M; Obata F; Harigae H; Takahashi S
Int J Mol Med; 2012 Feb; 29(2):319-23. PubMed ID: 22075620
[TBL] [Abstract][Full Text] [Related]
19. [Recurrent SPI1 fusions in pediatric T-cell acute lymphoblastic leukemia: novel mutations with poor prognosis].
Seki M; Takita J
Rinsho Ketsueki; 2018; 59(4):439-447. PubMed ID: 29743405
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic control of hematopoiesis: the PU.1 chromatin connection.
van Riel B; Rosenbauer F
Biol Chem; 2014 Nov; 395(11):1265-74. PubMed ID: 25205721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
